Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C28H34N4O2
CAS Number:
Molecular Weight:
458.60
MDL number:
NACRES:
NA.21
SMILES string
N4(CCCC4)C(=O)c1ccc(cc1)c2cc3c(cc2)C=C(C=C(N3)N)C(=O)N(CCC)CCC
InChI
1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-19,30H,3-6,13-16,29H2,1-2H3
InChI key
CQAGPRVMJDWWEA-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
Potent and selective toll-like receptor 8 (TLR8) agonist that augments the lytic function of NK cells and enhances antibody-dependent cellular cytotoxicity.
Motolimod (VTX-2337) is a potent and selective human toll-like receptor 8 (TLR8) agonist (EC50 = 100 nM; no murine TLR8-stimulating potenty) with greatly reduced TLR7 potency (EC50 >30 µM) and little activity toward TLR3/4/5/8. Motolimod induces proinflammatory mediators production in huaman PBMCs (TNFα/IL12 EC50 = 140/120 nM) by stimulating TLR8-expressing monocytes and mDCs, but not non-TLR8-expressing pDCs. Motolimod augments the lytic function of NK cells and enhances antibody-dependent cellular cytotoxicity (ADCC).
Motolimod (VTX-2337) is a potent and selective human toll-like receptor 8 (TLR8) agonist (EC50 = 100 nM; no murine TLR8-stimulating potenty) with greatly reduced TLR7 potency (EC50 >30 µM) and little activity toward TLR3/4/5/8. Motolimod induces proinflammatory mediators production in huaman PBMCs (TNFα/IL12 EC50 = 140/120 nM) by stimulating TLR8-expressing monocytes and mDCs, but not non-TLR8-expressing pDCs. Motolimod augments the lytic function of NK cells and enhances antibody-dependent cellular cytotoxicity (ADCC).
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yushe Dang et al.
Journal of leukocyte biology, 103(1), 157-164 (2018-01-19)
Myeloid-derived suppressor cells (MDSCs) accumulate in tumors and the peripheral blood of cancer patients and demonstrate cancer-promoting activity across multiple tumor types. A limited number of agents are known to impact MDSC activity. TLR8 is expressed in myeloid cells. We
Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
PLoS ONE, 11(2) (2016)
Hailing Lu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 18(2), 499-509 (2011-12-01)
We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its potential to improve monoclonal antibody-based immunotherapy that includes the activation of natural killer (NK) cells. HEK-TLR transfectants were used to compare the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service